In this online, self-learning activity:
Insomnia is defined by the dissatisfaction of sleep quality or quantity characterized by having difficulty falling asleep, staying asleep, waking too early, or a combination of these. It is defined as chronic if the condition persists for three months, despite the opportunity for sleep or eradication of external stimulus. Insomnia affects people of all ages, though the likelihood of developing insomnia increases with age: reporting one-third of the adult population having been affected by at least one symptom of insomnia.
This learning activity has been designed to bring healthcare professionals’ knowledge of the strategies for treatment of insomnia up to date and to improve their competence and performance in treating it. The activity will also focus on the role of novel pharmacotherapies in the management of insomnia.
The following HCPs: neurologists, psychiatrists, sleep medicine specialists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with insomnia.
Commercial Support Disclosure: This activity is supported by an educational grant from Eisai.
Learners may participate in this activity free of charge.
Release Date: October 18, 2019 -- Expiration Date: October 18, 2021
Faculty: Terese Hammond, MD
Faculty introductions, disclosures
Introduction content: cursory refresher and review of insomnia
Treatment of insomnia
– GABA agonists
– Selective melatonin receptor agonist
– Orexin receptor antagonists
Conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Terese Hammond, MD , has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Opioid dependence and opioid use disorder: Best practices, barriers in care, and the role of long-acting injectable medication
Updates in alcohol use disorder (AUD) pharmacotherapy and barriers to optimal care
Bipolar and mood disorder: Therapeutic updates and best practices
Addressing barriers to optimal care in schizophrenia with pharmacotherapy